Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC.
Yu HA, Baik C, Kim DW, Johnson ML, Hayashi H, Nishio M, Yang JC, Su WC, Gold KA, Koczywas M, Smit EF, Steuer CE, Felip E, Murakami H, Kim SW, Su X, Sato S, Fan PD, Fujimura M, Tanaka Y, Patel P, Sternberg DW, Sellami D, Jänne PA.
Yu HA, et al. Among authors: tanaka y.
Ann Oncol. 2024 May;35(5):437-447. doi: 10.1016/j.annonc.2024.02.003. Epub 2024 Feb 17.
Ann Oncol. 2024.
PMID: 38369013
Free article.
Clinical Trial.